Telomere length measurement as a clinical biomarker of aging and disease
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Telomere length measurement is increasingly recognized as a clinical gauge for age-related disease risk. There are several methods for studying blood telomere length (BTL) as a clinical biomarker. The first is an observational study approach, which directly measures telomere lengths using either cross-sectional or longitudinal patient cohorts and compares them to a population of age- and sex-matched individuals. These direct traceable measurements can be considered reflective of an individual's current health or disease state. Escalating interest in personalized medicine, access to high-throughput genotyping and resulting acquisition of large volumes of genetic data corroborates the second method, Mendelian randomization (MR). MR employs telomere length-associated genetic variants to indicate predisposition to disease risk based on the genomic composition of the individual. When assessed from cells in the bloodstream, telomeres can show variation from their genetically predisposed lengths due to environmental-induced changes. These alterations in telomere length act as an indicator of cellular health, which, in turn, can provide disease risk status. Overall, BTL measurement is a dynamic marker of biological health and well-being that together with genetically defined telomere lengths can provide insights into improved healthcare for the individual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 1×
“(TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) values [78,80].”
BackgroundStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis
Greider, C. W., & Blackburn, E. H. (1989) · Nature · doi:10.1038/337331a0 · Cited by 1,643
Blackburn, E. H., Epel, E. S., & Lin, J. (2015) · Science · doi:10.1126/science.aab3389 · Cited by 1,596 · cited 1×
“been associated with increased cancer risk [34,40,41].”
Control of telomere length by the human telomeric protein TRF1
van Steensel, B., & de Lange, T. (1997) · Nature · doi:10.1038/385740a0 · Cited by 1,219
Armanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982 · cited 2×
“Phenotypes associated with DC, include idiopathic pulmonary fibrosis, aplastic anemia, and cancer [11].”
BackgroundMendelian randomization as an instrumental variable approach to causal inference
Didelez, V., & Sheehan, N. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206077743 · Cited by 923
Leukocyte Telomere Length and Cardiovascular Disease in the Cardiovascular Health Study
Fitzpatrick, A. L., Kronmal, R. A., Gardner, J. P., Psaty, B. M., Jenny, N. S., Tracy, R. P., Walston, J., Kimura, M., & Aviv, A. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj346 · Cited by 773 · cited 3×
“At face value, these studies suggest that telomere length measurement and/or specific genetic variants could have CONTACT Clare L. Fasching cfasching@telomeredx.com Telomere Diagnostics, Inc., 3603 Haven Ave., Suite A Menlo Park, CA 94025, USA 2018 Informa UK Limited, trading as Taylor & Francis Group T2DM Bruneck Stu…”
BackgroundResult
Cited by
Vaiserman, A., & Krasnienkov, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.630186 · Cited by 454
“Therefore, TL is currently recognized by many authors as powerful biomarker of aging and aging-associated pathological conditions (Fasching, 2018).”
BackgroundGatto, N., Dos Santos Souza, C., Shaw, A. C., Bell, S. M., Myszczynska, M. A., Powers, S., Meyer, K., Castelli, L. M., Karyka, E., Mortiboys, H., et al. (2021) · Aging Cell · doi:10.1111/acel.13281 · Cited by 58
“It is well known that telomerase activity is crucial in determining telomere length in ageing cells and that telomere length can be considered as a biomarker of chronological ageing (Fasching, 2018; Rizvi et al., 2015).”
BackgroundTelomeres as Therapeutic Targets in Heart Disease
Yeh, J.-K., Lin, M.-H., & Wang, C.-Y. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.009 · Cited by 49
Metadata
- Authors
- Fasching, C. L.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2018-09-28
- Volume
- 55
- Issue
- 7
- Pages
- 443-465
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2894323088
- Cited by
- 167
- References
- 45
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomere length measurement as a clinical biomarker of aging and disease. https://app.cochat.ai/papers/10.1080/10408363.2018.1504274
- The paper
- Fasching, C. L. (2018). Telomere length measurement as a clinical biomarker of aging and disease. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.1080/10408363.2018.1504274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.